APDN Plunges to $3.98M Loss Amid Strategic Restructuring

TL;DR

**BNBX is bleeding cash and undergoing a massive restructuring; this is a high-risk bet on a turnaround that's far from guaranteed.**

AI Summary

APPLIED DNA SCIENCES INC. (BNBX) reported a significant net loss of $3,984,109 for the three months ended June 30, 2025, a stark contrast to the net income of $1,849,501 in the prior-year period. For the nine months ended June 30, 2025, the net loss widened to $9,988,942 from $3,774,563 in the same period last year. Total revenues decreased by 35.6% to $304,393 for the three-month period, primarily due to a 20.8% drop in product revenues to $195,262 and a 51.7% decline in service revenues to $109,131. However, nine-month total revenues increased by 19.1% to $1,937,506. The company is undergoing a strategic restructuring, exiting its DNA Tagging and Security Products and Services business and ceasing MDx Testing Services, resulting in a 39% reduction in headcount and projected 31% total reduction in annual payroll expenses compared to fiscal year 2024. Cash and cash equivalents stood at $4,727,677 as of June 30, 2025, down from $5,852,363 at September 30, 2024, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

This filing reveals a company in a critical transition, shedding non-core assets to focus on nucleic-acid production. For investors, the substantial net losses and 'going concern' warning signal high risk, despite the strategic pivot. Employees in the discontinued DNA Tagging and Security and MDx Testing Services businesses face job insecurity, with a 39% headcount reduction already implemented. Customers of the discontinued services will need to find alternative providers. The broader market will watch if APDN's focused biopharmaceutical strategy can yield profitability, especially given the competitive landscape in gene therapies and mRNA therapeutics.

Risk Assessment

Risk Level: high — The company explicitly states 'These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the date of issuance of these financial statements.' This is evidenced by a net loss from continuing operations of $9,585,822 and negative operating cash flow from continuing operations of $9,141,688 for the nine-month period ended June 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor the company's ability to secure additional capital and demonstrate tangible progress in its focused biopharmaceutical and diagnostics segments before considering any position.

Financial Highlights

debt To Equity

0.42

revenue

$304,393

operating Margin

N/A

total Assets

$9,934,746

total Debt

$2,946,702

net Income

-$3,984,109

eps

N/A

gross Margin

N/A

cash Position

$4,727,677

revenue Growth

-35.6%

Revenue Breakdown

Key Numbers

• $3,984,109 — Net Loss (3 months ended June 30, 2025) (Increased from net income of $1,849,501 in prior-year period)
• $9,988,942 — Net Loss (9 months ended June 30, 2025) (Widened from $3,774,563 in prior-year period)
• $304,393 — Total Revenues (3 months ended June 30, 2025) (Decreased by 35.6% from $472,789 in prior-year period)
• $1,937,506 — Total Revenues (9 months ended June 30, 2025) (Increased by 19.1% from $1,625,863 in prior-year period)
• $4,727,677 — Cash and Cash Equivalents (June 30, 2025) (Decreased from $5,852,363 at September 30, 2024)
• 39% — Total Headcount Reduction (Since January 2025, due to strategic restructuring)
• 31% — Projected Total Reduction in Annual Payroll Expenses (Compared to fiscal year ended September 30, 2024)
• $9,585,822 — Net Loss from Continuing Operations (9 months ended June 30, 2025) (Key factor in 'going concern' doubt)
• $9,141,688 — Negative Operating Cash Flow from Continuing Operations (9 months ended June 30, 2025) (Key factor in 'going concern' doubt)
• 1,291,465 — Shares of Common Stock Outstanding (August 12, 2025) (Reflects impact of 2025 Reverse Splits)

Key Players & Entities

• APPLIED DNA SCIENCES INC. (company) — registrant
• LineaRx, Inc. (company) — wholly-owned subsidiary
• Applied DNA Clinical Labs (company) — wholly-owned subsidiary, operations ceased
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Stock Market LLC (company) — exchange where common stock is registered
• Delaware (regulator) — State of incorporation
• June 30, 2025 (date) — end of reporting period
• September 30, 2024 (date) — end of prior fiscal year
• March 14, 2025 (date) — effective date of 1:50 reverse stock split
• June 2, 2025 (date) — effective date of 1:15 reverse stock split

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's cash and cash equivalents decreased to $4,727,677 as of June 30, 2025, from $5,852,363 at September 30, 2024. Coupled with a net loss of $9,988,942 for the nine months ended June 30, 2025, and negative operating cash flow from continuing operations of $9,141,688, this raises substantial doubt about its ability to continue as a going concern.
• Strategic Restructuring Impact [high — operational]: The company is undergoing a significant strategic restructuring, including exiting its DNA Tagging and Security Products and Services business and ceasing MDx Testing Services. This has led to a 39% reduction in headcount and a projected 31% reduction in annual payroll expenses, which may impact ongoing operations and future revenue streams.
• Revenue Decline in Key Segments [medium — market]: Total revenues for the three months ended June 30, 2025, decreased by 35.6% to $304,393. This decline was driven by a 20.8% drop in product revenues and a substantial 51.7% decline in service revenues, indicating potential market challenges or shifts in demand.
• Widening Net Loss [high — financial]: The net loss for the nine months ended June 30, 2025, widened to $9,988,942 from $3,774,563 in the same period last year. The net loss from continuing operations was $9,585,822, highlighting ongoing profitability challenges.
• Decreased Current Assets [medium — financial]: Total current assets decreased from $8,047,671 at September 30, 2024, to $5,628,902 at June 30, 2025. This reduction, particularly in cash and cash equivalents and prepaid expenses, could limit operational flexibility.
• Discontinued Operations Impact [low — operational]: Current assets of discontinued operations fell from $678,146 to $25,008, and noncurrent assets of discontinued operations decreased from $94,337 to $11,264. While exiting these segments is part of the strategy, the associated asset write-downs and wind-downs can be complex.

Industry Context

Applied DNA Sciences operates in the specialized fields of DNA-based security and authentication. The industry is characterized by rapid technological advancements and a growing demand for solutions to combat counterfeiting and ensure product integrity across various sectors like pharmaceuticals, agriculture, and luxury goods. However, it faces competition from established players and emerging technologies, requiring continuous innovation and market penetration.

Regulatory Implications

The company's operations, particularly in DNA tagging and testing, may be subject to various regulatory standards depending on the end markets served. Changes in these regulations or compliance failures could impact product development, market access, and operational costs. The restructuring also involves managing the wind-down of certain services, which may have specific regulatory considerations.

What Investors Should Do

1. Monitor the execution of the strategic restructuring plan and its impact on future revenue and cost structures.
2. Closely evaluate the company's cash burn rate and its ability to secure additional funding to address going concern issues.
3. Assess the long-term viability of the remaining business segments and their potential for profitability post-restructuring.
4. Analyze the competitive landscape and the company's ability to differentiate its offerings in the DNA technology market.

Key Dates

• 2025-06-30: End of Third Quarter of Fiscal Year 2025 — Reporting period for the 10-Q, showing significant net loss and revenue decline, and highlighting going concern issues.
• 2025-09-30: End of Fiscal Year 2024 — Prior period balance sheet date for comparison of cash and cash equivalents and total assets/liabilities.

Glossary

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, a critical disclosure for investors.)

Discontinued Operations

A component of a business that has been disposed of or is classified as held for sale, and represents a separate major line of business or geographical area of operations. (The company is exiting certain business lines, and their financial results are reported separately as discontinued operations.)

Accumulated Deficit

The total net losses of a company since its inception that have not been offset by net income. (The company has a significant accumulated deficit of $373,888,601 as of June 30, 2025, indicating a history of unprofitability.)

Operating Right of Use Asset

An asset recognized under lease accounting standards, representing the lessee's right to use an underlying asset for the lease term. (This asset has decreased significantly, reflecting the company's restructuring and potential reduction in leased facilities or equipment.)

Year-Over-Year Comparison

Compared to the prior-year period, Applied DNA Sciences has experienced a significant downturn in its quarterly performance, with total revenues for the three months ended June 30, 2025, dropping 35.6% and shifting from net income to a substantial net loss of $3,984,109. While nine-month revenues saw an increase, the overall financial health is challenged by a widening net loss and reduced cash reserves, compounded by a major strategic restructuring involving headcount reductions and business exits.

Key Financial Figures

• $0.001 — ge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar

Filing Documents

• apdn-20250630x10q.htm (10-Q) — 1973KB
• apdn-20250630xex31d1.htm (EX-31.1) — 13KB
• apdn-20250630xex31d2.htm (EX-31.2) — 13KB
• apdn-20250630xex32d1.htm (EX-32.1) — 7KB
• apdn-20250630xex32d2.htm (EX-32.2) — 7KB
• 0001410578-25-001814.txt ( ) — 8985KB
• apdn-20250630.xsd (EX-101.SCH) — 54KB
• apdn-20250630_cal.xml (EX-101.CAL) — 56KB
• apdn-20250630_def.xml (EX-101.DEF) — 250KB
• apdn-20250630_lab.xml (EX-101.LAB) — 411KB
• apdn-20250630_pre.xml (EX-101.PRE) — 350KB
• apdn-20250630x10q_htm.xml (XML) — 1912KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

- Condensed Consolidated Financial Statements (unaudited)

Item 1 - Condensed Consolidated Financial Statements (unaudited) 1

- Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 24

- Quantitative and Qualitative Disclosures About Market Risk

Item 3 - Quantitative and Qualitative Disclosures About Market Risk 34

- Controls and Procedures

Item 4 - Controls and Procedures 35

- OTHER INFORMATION

PART II - OTHER INFORMATION

– Legal Proceedings

Item 1 – Legal Proceedings 36

– Risk Factors

Item 1A – Risk Factors 36

– Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 36

– Defaults Upon Senior Securities

Item 3 – Defaults Upon Senior Securities 36

– Mine Safety Disclosures

Item 4 – Mine Safety Disclosures 36

– Other Information

Item 5 – Other Information 36

– Exhibits

Item 6 – Exhibits 37 Table of Contents

- Financial Information

Part I - Financial Information

- Financial Statements

Item 1 - Financial Statements APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, September 30, 2025 2024 ASSETS (unaudited) Current assets: Cash and cash equivalents $ 4,727,677 $ 5,852,363 Accounts receivable, net of allowance for credit losses of $ 80,423 and $ 75,000 at June 30, 2025 and September 30, 2024, respectively 199,047 328,252 Inventories 338,723 432,725 Prepaid expenses and other current assets 338,447 756,185 Current assets of discontinued operations 25,008 678,146 Total current assets 5,628,902 8,047,671 Property and equipment, net 511,203 458,895 Noncurrent assets of discontinued operations 11,264 94,337 Other assets: Restricted cash 750,000 750,000 Intangible assets 2,698,975 2,698,975 Operating right of use asset 334,402 739,162 Total assets $ 9,934,746 $ 12,789,040 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued liabilities $ 1,564,707 $ 1,737,366 Operating lease liability, current 334,403 545,912 Deferred revenue 12,285 58,785 Current liabilities of discontinued operations 124,565 56,061 Total current liabilities 2,035,960 2,398,124 Long term accrued liabilities 31,467 31,467 Deferred revenue, long term 194,000 194,000 Operating lease liability, long term — 193,249 Deferred tax liability, net 684,115 684,115 Warrants classified as a liability 1,160 320,000 Total liabilities 2,946,702 3,820,955 Commitments and contingencies (Note G) Applied DNA Sciences, Inc. stockholders' equity: Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; - 0 - shares issued and outstanding as of June 30, 2025 and September 30, 2024 — — Series A Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; - 0 - issued and outstanding as of June 30, 2025 and September 30, 2024 — — Series B Preferred stock, par value $

View Full Filing

View this 10-Q filing on SEC EDGAR